Since tyrosine kinase inhibitors targeting aberrant products of gene alterations, such as the anaplastic lymphoma receptor tyrosine kinase (ALK), epidermal growth factor receptor (EGFR), ROS1 proto-oncogene receptor tyrosine kinase (ROS), and RET proto-oncogene receptor tyrosine kinase (RET) were introduced [6–10], the prognosis of patients suffering from non-small-cell lung cancer has drastically improved [5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.